CX Institutional Cuts Stock Position in HCA Healthcare, Inc. $HCA

Key Points

• CX Institutional reduced its stake in HCA Healthcare by 4.2%, holding 19,857 shares valued at approximately $7.6 million as of the latest reporting period.
• Wall Street analysts provide a mixed outlook for HCA Healthcare, with the average price target set at $407.75 and various ratings ranging from "Strong Buy" to "Hold."
• HCA Healthcare recently announced a quarterly dividend of $0.72 per share, with an ex-dividend date of September 16, resulting in an annual yield of 0.7%.

CX Institutional lowered its stake in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 19,857 shares of the company's stock after selling 869 shares during the quarter. CX Institutional's holdings in HCA Healthcare were worth $7,607,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of HCA. Brighton Jones LLC bought a new position in HCA Healthcare in the 4th quarter valued at $1,021,000. Vident Advisory LLC grew its position in HCA Healthcare by 8.2% in the 4th quarter. Vident Advisory LLC now owns 1,949 shares of the company's stock valued at $585,000 after acquiring an additional 147 shares during the last quarter. Waverly Advisors LLC bought a new position in HCA Healthcare in the 4th quarter valued at $439,000. City National Bank of Florida MSD bought a new position in HCA Healthcare in the 4th quarter valued at $229,000. Finally, Vise Technologies Inc. lifted its holdings in shares of HCA Healthcare by 195.9% in the 4th quarter. Vise Technologies Inc. now owns 5,407 shares of the company's stock worth $1,623,000 after buying an additional 3,580 shares during the period. Institutional investors own 62.73% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. upped their target price on HCA Healthcare from $360.00 to $370.00 and gave the stock a "neutral" rating in a report on Monday, August 4th. Barclays upped their target price on HCA Healthcare from $390.00 to $445.00 and gave the stock an "overweight" rating in a report on Thursday. Wolfe Research cut HCA Healthcare from an "outperform" rating to a "peer perform" rating in a report on Monday, July 28th. Wells Fargo & Company decreased their price objective on HCA Healthcare from $385.00 to $375.00 and set an "equal weight" rating for the company in a research note on Thursday, August 14th. Finally, Robert W. Baird upped their price objective on HCA Healthcare from $380.00 to $423.00 and gave the stock a "neutral" rating in a research note on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $407.75.

Insider Activity at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the sale, the executive vice president directly owned 31,503 shares in the company, valued at $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is owned by company insiders.

HCA Healthcare Stock Performance

HCA stock traded up $1.00 during trading on Friday, hitting $402.06. 4,308,470 shares of the company traded hands, compared to its average volume of 1,238,651. The stock's 50-day simple moving average is $385.21 and its 200 day simple moving average is $366.40. The company has a debt-to-equity ratio of 69.07, a current ratio of 0.98 and a quick ratio of 0.86. The company has a market cap of $94.08 billion, a PE ratio of 16.90, a P/E/G ratio of 1.27 and a beta of 1.41. HCA Healthcare, Inc. has a 1 year low of $289.98 and a 1 year high of $420.98.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its quarterly earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating the consensus estimate of $6.20 by $0.64. The company had revenue of $18.61 billion during the quarter, compared to analysts' expectations of $18.49 billion. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.HCA Healthcare's quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the business earned $5.50 earnings per share. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, equities analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.7%. The ex-dividend date is Tuesday, September 16th. HCA Healthcare's dividend payout ratio (DPR) is currently 12.11%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.